Neuropsychiatric Disorder

People who engage in moderate to vigorous physical activity may be less likely to develop dementia, stroke, anxiety, depression and sleep disorders compared with those with more sedentary behavior, according to preliminary study results.

Montelukast does not appear to increase the risk for neuropsychiatric adverse events in children and adolescents, according to a study published in JAMA Pediatrics.

Nightmares and hallucinations may occur at any stage of disease course in patients with systemic lupus erythematosus, according to recent findings.

Rates of adverse events were similar in both the pimavanserin group and placebo group.Pimavanserin was well-tolerated and not associated with cognitive decline or motor dysfunction in older adults with Parkinson’s disease and neuropsychiatric symptoms, according to a poster presentation.

For adults in the U.K., preexisting neuropsychiatric conditions and having a prescription for a related treatment carried a significantly increased risk of severe outcomes from COVID-19 and other severe acute respiratory infections.

Neurocrine Biosciences and Sosei Group Corporation have announced a partnership to create a new brand of protein inhibitor that the former plans to study to improve treatments for a wide range of neuropsychiatric disorders.

The use of stimulant medications has been an integral aspect for the pharmacotherapy of ADHD for more than 50 years. Numerous published studies have documented their efficacy to reduce symptoms of ADHD in children older than age 4 years. As with any medication, however, adverse effects occur, and these adverse effects must be balanced against the medication’s benefit for each individual patient. The potential for a negative adverse effect on growth from stimulant medications has been discussed in the literature for years.

The ongoing COVID-19 pandemic and measures to combat the spread of the virus have significantly impacted the mental health of individuals throughout the United States and the world.

Individuals who recover from COVID-19 infection may experience a significant neuropsychiatric burden long after the current pandemic, according to authors of a review article published in Brain, Behavior, and Immunity. Thus, researchers should conduct prospective neuropsychiatric and neuroimmune monitoring of those exposed to SARS-CoV-2 at various points in the life course to better understand the long-term impact of COVID-19, as well as to create a framework for the integration of psychoneuroimmunology into epidemiologic studies of pandemics, the authors noted.